Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.23% to $8.51 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.

Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and ...

BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will ...

Check the time stamp on this data. Updated AI-Generated Signals for Corvus Pharmaceuticals Inc. (CRVS) available here: CRVS.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has received a consensus rating of “Buy” from the five analysts that are presently covering the firm, Marketbeat reports.

Corvus Pharmaceuticals, Inc. (CRVS) stock price is 5.36 and Corvus Pharmaceuticals, Inc. (CRVS) 10-day simple moving average is 5.21. Corvus Pharmaceuticals, Inc. (CRVS) stock price is 5.36 and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Corvus Pharmaceuticals Inc . (NASDAQ:CRVS) stock has reached a remarkable 52-week high, touching $8.74 amidst a period of significant growth. This milestone reflects a... Corvus Pharmaceuticals ...